GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
+25.08%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$311M
AUM Growth
+$311M
(+79%)
Cap. Flow
+$122M
Cap. Flow
% of AUM
39.1%
Top 10 Holdings %
Top 10 Hldgs %
41.8%
Holding
78
New
28
Increased
24
Reduced
11
Closed
7
Top Buys
| 1 |
MoonLake Immunotherapeutics
MLTX
|
$11.1M |
| 2 |
TG Therapeutics
TGTX
|
$8.75M |
| 3 |
Apellis Pharmaceuticals
APLS
|
$7.64M |
| 4 |
Roivant Sciences
ROIV
|
$7.38M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$6.9M |
Top Sells
| 1 |
AMAM
Ambrx Biopharma, Inc. Common Stock
AMAM
|
$6.76M |
| 2 |
Krystal Biotech
KRYS
|
$6.41M |
| 3 |
argenx
ARGX
|
$5.71M |
| 4 |
Taysha Gene Therapies
TSHA
|
$3.3M |
| 5 |
Structure Therapeutics
GPCR
|
$3.21M |
Sector Composition
| 1 | Healthcare | 99.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Tenaya Therapeutics
TNYA
$192M
| $4.05M | 1.12% |
+775,000
| New | +$4.05M |
|
27
Immunovant
IMVT
$2.91B
| $4.04M | 1.12% |
+125,000
| New | +$4.04M |
|
28
Spyre Therapeutics
SYRE
$1.02B
| $3.79M | 1.05% |
+100,000
| New | +$3.79M |
|
29
Syndax Pharmaceuticals
SNDX
$1.39B
| $3.57M | 0.99% |
+150,000
| New | +$3.57M |
|
30
enGene Holdings
ENGN
$249M
| $3.39M | 0.94% |
+200,000
| New | +$3.39M |
|
31
CG Oncology
CGON
$2.19B
| $3.29M | 0.91% |
+75,000
| New | +$3.29M |
|
|
32
Structure Therapeutics
GPCR
$1.14B
| $3.21M | 0.89% |
75,000
-75,000
| -50% | -$3.21M |
|
|
BBOT
33
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$779M
| $3.12M | 0.86% |
+300,000
| New | +$3.12M |
|
34
Cogent Biosciences
COGT
$1.83B
| $3.02M | 0.84% |
450,000
+255,000
| +131% | +$1.71M |
|
35
Aquestive Therapeutics
AQST
$478M
| $2.99M | 0.83% |
+702,941
| New | +$2.99M |
|
|
DCPH
36
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $2.78M | 0.77% |
176,513
-48,487
| -22% | -$763K |
|
|
37
Taysha Gene Therapies
TSHA
$791M
| $2.73M | 0.75% |
950,000
-1,150,000
| -55% | -$3.3M |
|
38
Geron
GERN
$893M
| $2.64M | 0.73% |
+800,000
| New | +$2.64M |
|
|
MRNS
39
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $2.58M | 0.71% |
285,000
+150,000
| +111% | +$1.36M |
|
40
Altimmune
ALT
$325M
| $2.55M | 0.7% |
+250,000
| New | +$2.55M |
|
41
Regenxbio
RGNX
$498M
| $2.53M | 0.7% |
+120,000
| New | +$2.53M |
|
|
42
Krystal Biotech
KRYS
$4.35B
| $2.49M | 0.69% |
14,000
-36,000
| -72% | -$6.41M |
|
43
KalVista Pharmaceuticals
KALV
$713M
| $2.37M | 0.66% |
200,000
+69,964
| +54% | +$830K |
|
44
Natera
NTRA
$23B
| $2.29M | 0.63% |
25,000
-10,000
| -29% | -$915K |
|
45
Olema Pharmaceuticals
OLMA
$432M
| $2.26M | 0.63% |
+200,000
| New | +$2.26M |
|
46
Corbus Pharmaceuticals
CRBP
$121M
| $2.23M | 0.62% |
+56,941
| New | +$2.23M |
|
|
RVNC
47
DELISTED
Revance Therapeutics, Inc.
RVNC
| $2.21M | 0.61% |
450,000
+75,000
| +20% | +$369K |
|
48
Protagonist Therapeutics
PTGX
$3.62B
| $2.17M | 0.6% |
75,000
-50,000
| -40% | -$1.45M |
|
49
EyePoint Pharmaceuticals
EYPT
$827M
| $1.86M | 0.51% |
90,000
-75,000
| -45% | -$1.55M |
|
50
Madrigal Pharmaceuticals
MDGL
$9.7B
| $1.74M | 0.48% |
6,500
-8,500
| -57% | -$2.27M |
|